Discontinued — last reported Q4 '18
Eli Lilly Available-for-Sale Debt Securities - Accumulated Gross Unrealized Gain (Before Tax) decreased by 24.9% to $177.60M in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 36.1%, from $278.00M to $177.60M. Over 4 years (FY 2020 to FY 2024), Available-for-Sale Debt Securities - Accumulated Gross Unrealized Gain (Before Tax) shows a downward trend with a -20.0% CAGR.
afs_debt_securities_unrealized_gain_before_tax| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $338.10M | $293.40M | $250.70M | $89.50M | $28.80M | $13.80M | $46.80M | $120.50M | $54.60M | $30.40M | $159.20M | $111.80M | $104.70M | $278.00M | $142.60M | $216.60M | $236.40M | $177.60M |
| QoQ Change | — | -13.2% | -14.6% | -64.3% | -67.8% | -52.1% | +239.1% | +157.5% | -54.7% | -44.3% | +423.7% | -29.8% | -6.4% | +165.5% | -48.7% | +51.9% | +9.1% | -24.9% |
| YoY Change | — | — | — | — | -91.5% | -95.3% | -81.3% | +34.6% | +89.6% | +120.3% | +240.2% | -7.2% | +91.8% | +814.5% | -10.4% | +93.7% | +125.8% | -36.1% |
We use cookies for analytics. See our Privacy and Cookie Policy.